A new electroneutral half-sandwich tantalum(V) dichlorido complex containing pentamethylcyclopentadienyl (Cp*) and the double-deprotonated version of the Schiff base 2-ethoxy-6-{(E)-[(2-hydroxyphenyl)imino]methyl}phenol (H2L) as ligands, namely cis-dichlorido(2-ethoxy-6-{(E)-[(2-oxidophenyl)imino]methyl}phenolato-κ3O,N,O')(η5-pentamethylcyclopentadienyl)tantalum(V), [Ta(C10H15)(C15H13NO3)Cl2] or [Ta(η5-Cp*)(L)Cl2], has been prepared and thoroughly characterized by elemental analysis, IR and NMR spectroscopy, mass spectrometry, density functional theory (DFT) calculations and single-crystal X-ray diffraction. The molecular structure revealed that the TaV centre is coordinated by a η5-Cp* ligand, two monodentate chlorido ligands and one O,N,O'-tridentate L2- ligand. The crystal structure is stabilized by C-H...C, C-H...Cl and C...C intermolecular interactions. Moreover, the complex shows notable in vitro cytotoxicity against the A2780 human ovarian carcinoma cell line, with IC50 = 14.4 µM, which is higher than that of the conventional platinum-based anticancer drug cisplatin (IC50 = 20.1 µM).

Division of Biologically Active Complexes and Molecular Magnets Regional Centre of Advanced Technologies and Materials Faculty of Science Palacký University in Olomouc Šlechtitelů 27 78371 Olomouc Czech Republic

References provided by Crossref.org

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-5